

# Uniform Protocols for Imaging in Clinical Trials – UPICT Clinical and Translational Science Awards Imaging Working Group: **Clinical Trials Committee**

### **Background**

Imaging is used in clinical trials for a variety of purposes, (e.g., determining eligibility, triage for subgroup analyses, response assessment, and endpoint measurements). Variance in imaging-derived data in clinical trials detracts from the value that imaging might contribute. Multiple factors other than biology contribute to this variance, such as technical differences among vendor platforms, machine drift over time, and changes introduced by services calls and system upgrades.

Imaging biomarkers (quantitative whenever possible) could contribute to decreased sample size through enrichment of the accrued cohort and to shortening the clinical trial's duration through the use of imaging as an early predictive surrogate endpoint. In order for imaging to fulfill this promise, non-biologic variance (noise) must be reduced so that signal is 1) sufficiently conspicuous and 2) a consequence of the intervention under investigation in the trial rather than to some artifact of the manner in which the imaging is conducted.

In order to improve the reliability of imaging in clinical trials, the CTSA Imaging Working Group (CTSA-IWG) promulgates Uniform Protocols for Imaging in Clinical Trials (UPICT).

#### **UPICT Concept and Goals:**

To facilitate the development and maintenance of consistent imaging protocols (including imaging quality control procedures) for use in clinical trials:

•to "improve" the contribution of imaging data, including increased statistical power,

·while supporting robust case accrual,

•and decreasing time to study initiation and site activation:

·while facilitating image data aggregation across trials and \*supporting the development, optimization, validation, and qualification of imaging biomarkers:

 through the participation of imaging scientists and clinical trialists drawn from the broad range of interested constituencies.

In addition, UPICT provides an impetus to improve the consistency of imaging performed during routine clinical care (thereby increasing the chances that pre-enrollment imaging might be used as the "baseline" study for clinical trials). Furthermore, as interventions translate from clinical trials to clinical care so too will the standardized imaging protocols translate from a supporting role in trials to clinical practice.

In order to actualize the UPICT concept and goals, the CTSA-IWG has established and implemented specific objectives, strategies, and activities (see next panel).

## **Objectives**

UPICT has established the following objectives:

 Provide a standardized template to facilitate the authoring of, comparison among, and use of imaging protocols for clinical trials

 Provide a searchable library of imaging protocols that have been used in single- and multi-site clinical trials ·Provide a searchable library of consensus protocols that are endorsed by pertinent experts and organizations Provide a forum for clinical trialists and imaging scientists to collaborate on improving the value of imaging protocols in clinical trials

•Ensure that UPICT is transparent and inclusive ·Avoid duplication of other clinical trial imaging protocol development efforts (but instead include their work products within the UPICT infrastructure)

## **Strategies / Activities**

UPICT has implemented the following strategies and activities:

•Inclusion of CTSA and non-CTSA representation in all **UPICT** activities including monthly web-based meetings (i.e., imaging device industry, PhRMA, BIO, federal agencies, CROs, academia, and clinical imaging practices)

Formal workflow for UPICT Processes

·Invite contribution of clinical trial imaging protocols from academia (single- and multi-site) and industry (device. PhRMA, BIO, CRO) trials (Proffered Protocols)

 Engagement of the QIBA Technical Committees which are also contributing Proffered Protocols) •Established UPICT web site / wiki under the CTSA-IWG

with specific workspaces for the authoring, vetting, annotation, and editing of protocols -

http://upictwiki.ctsa-imaging.org

•Finalized UPICT Template v1.0 ·Writing groups authoring Consensus Protocols using the UPICT Template for posting in the Consensus Library:

- Oncologic FDG-PET

- Oncologic vCT

- COPD / Asthma CT - MRI for AD / MCI Currently extracting Proffered Protocols into the UPICT Template for posting in the Proffered Protocol Library:

ACRIN

- vCT

- FDG-PET - MRI

ACOSOG

- DCE-CT

ADNI and ADNI II

QIBA - Oncologic vCT - Oncologic FDG-PET

- DCE-MRI COPD / Asthma CT

 CALGB various

 Netherlands and EANM - Whole-body FDG-PET

FDG and βAmyloid-PET

JOIN THE UPICT EFFORT CONTACT US AT: upict@rsna.org

## **UPICT Template v1.0**

Context of the Imaging Protocol within the Clinical Trial
 1.1. Utilities and Endpoints of the Imaging Protocol

1.2. Timing of Imaging within the Clinical Trial Calendar
 1.3. Management of Pre-enrollment Imaging
 1.4. Management of Protocol Imaging Performed Off-schedule

1.5. Management of Protocol Imaging Performed Off-specification
1.6. Management of Off-protocol Imaging
1.7. Subject Selection Criteria Related to Imaging

1.7.1. Relative Contraindications and Remediations

172 Absolute Contraindications and Alternatives

1.7.3. Imaging-specific Inclusion Criteria

2. Site Selection, Qualification and Training

2.1. Personnel Qualifications 2.1.1. Technical

2.1.2. Physics

2.1.4. Other (e.g., radiochemistry, radiobiologist, pharmacist, etc.)

2.2. Imaging Equipment 2.3. Infrastructure

2.4. Quality Control

241 Procedures

2.4.2. Baseline Metrics Submitted Prior to Subject Accrual

2.4.3. Metrics Submitted Periodically During the Trial

2.5. Protocol-specific Training

Subject Scheduling
 3.1. Timing Relative to Index Intervention Activity

Timing Relative to confounding Activities (to minimize "impact")

3.3. Scheduling Ancillary Testing

4.2 Upon Arrival

4.2.1. Confirmation of subject compliance with instructions 4.2.2. Ancillary Testing

4.2.3. Preparation for Exam

5. Imaging-related Substance Preparation and Administration

Substance Description and Purpose

5.3. Timing, Subject Activity Level, and Factors Relevant to Initiation of Image Data

5.4. Administration Route 5.5. Rate, Delay and Related Parameters / Apparatus

5.6. Required Visualization / Monitoring, if any

5.7. Quality Control

6. Individual Subject Imaging-related Quality Control

7. Imaging Procedure

Required Characteristics of Resulting Data 7.1.1 Data Content 7.1.2. Data Structure

7.1.3. Data Quality
Imaging Data Acquisition
7.2.1. Subject Positioning

7.2.2. Instructions to Subject During Acquisition 7.2.3. Timing/Triggers
7.2.4. Model-Specific Parameters

7.2.5. Archival Requirements for Primary Source Imaging Data Imaging Data Reconstruction
7.3.1. Model-Specific Parameters

7.3.2. Archival Requirements for Reconstructed Imaging Data

Image Post-processing

8.3. Required Characteristics of Resulting Data

8.6. Quality Control

## **UPICT Template v1.0**

9. Image Analysis

9.1. Input Data to Be Used 9.2. Methods to Be Used 9.3. Required Characteristics of Resulting Data

9.4. Platform-specific Instructions

10.1. Input Data to Be Used 10.2. Methods to Be Used

10.3. Required Characteristics of Resulting Data

10.4. Platform-specific Instructions 10.5. Reader Training 10.6. Archival Requirements

10.7. Quality Control

11. Archival and Distribution of Data

11.1. Central Management of Imaging Data
11.2. De-identification / Anonymization Schema(s) to Be Used

11.3. Primary Source Imaging Data

11.4. Reconstructed Imaging Data 11.5. Post-Processed Data

11.7. Interpretation Results and Reporting

12. Quality Control

12.1. QC Associated with the Site

12.1.1. Quality Control Procedures
12.1.2. Baseline Metrics Submitted Prior to Subject Accrual

12.1.2 Baseline metrics Summer Producially During the Trial
12.1.3 Metrics Submitted Periodically During the Trial
12.2 QC Associated with Imaging-related Substance Preparation and Administration
12.3 QC Associated with Individual Subject Imaging

12.3.1. Phantom Imaging and/or Calibration
12.3.2. Quality Control of the Subject Image and Image Data

12.3.2. Quality Control of the Subject Ima 12.4. QC Associated with Image Reconstructio 12.5. QC Associated with Image Processing 12.6. QC Associated with Image Analysis

12.7 OC Associated with Inte

13 Imaging-associated Risks and Risk Management

13.1. Radiation Dose and Safety Considerations
13.2. Imaging Agent Dose and Safety Considerations

Imaging Hardware-specific Safety Considerations
 Management and Reporting of Adverse Events Associated with Imaging Agent and Enhancer Administration

13.5. Management and Reporting of Adverse Events Associated with Image Data Acquisition

Appendix A. Acknowledgements and Attributions

Appendix B. Background Information Appendix C. Conventions and Definitions

Appendix D. Documents included in the imaging protocol (e.g., CRFs)
Appendix E. Associated Documents (derived from the imaging protocol or supportive of
the imaging protocol; e.g., Imaging Charter, Site Manual, SOPs)
Appendix F. TBD

Appendix G. Model-specific Instructions and Parameters

#### Considerations

UPICT Consensus Protocols should 1) account for variations in current technology and 2) accommodate continued technological evolution 3) while maintaining protocol stability using versioning: 4) provide detail sufficient to ensure consistency and reproducibility while 5) incorporating placeholders for trial / disease-specific parameters; 6) accommodate standard of care imaging to the extent possible; 7) facilitate accrual; and 8) support the needs of academia, agencies, and industry.

UPICT Proffered and Consensus Protocols recognize the variable capabilities of clinical trial imaging sites worldwide by incorporating Acceptable, Target, and Ideal parameters to which participating sites adhere.